Gilead Sciences | GILD - Interest Income


Gilead Sciences reported $95M in Interest Income for its fiscal quarter ending in December of 2025.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Agios Pharmaceuticals USD 12.41M 959K Dec/2025
ALKERMES USD 8.54M 3.59M Mar/2026
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 7M Dec/2025
GlaxoSmithKline GBP 22M 96M Mar/2026
Glaxosmithkline GBP 22M 4M Mar/2026
Incyte USD 33.69M 2.93M Mar/2026
J&J USD 2.14 237M Mar/2026
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Pfizer USD 115M 51M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 33M 81M Dec/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
United Therapeutics USD 43.2M 3.2M Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026